Safety and feasibility of complete simultaneous revascularization during primary PCI in patients with STEMI and multi-vessel disease  by Maamoun, Walid et al.
The Egyptian Heart Journal (2011) 63, 39–43Egyptian Society of Cardiology
The Egyptian Heart Journal
www.elsevier.com/locate/ehj
www.sciencedirect.comORIGINAL ARTICLESafety and feasibility of complete
simultaneous revascularization during primary PCI
in patients with STEMI and multi-vessel diseaseWalid Maamoun a,*, Nabil Elkhaeat b, Rasha Elarasy ba Cardiology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
b Cardiology Department, University of Science and Technology Hospital, Sanaa, YemenReceived 13 September 2010; accepted 26 October 2010
Available online 14 October 2011*
E
11
ho
Pe
doKEYWORDS
Primary PCI;
Acute STEMI;
Multi-vessel diseaseCorresponding author.
-mail address: walidmaamou
10-2608 ª 2011 Egyptian S
sting by Elsevier B.V. All rig
er review under responsibilit
i:10.1016/j.ehj.2011.08.030
Production and hn2005@
ociety of
hts reser
y of Egyp
osting by EAbstract Background: Contemporary guidelines recommend to dilate only the infarct-related-
artery (culprit only revascularization) during the initial procedure in patients with STEMI and
multi-vessel disease treated with 1ry PCI, leaving the other stenosed vessels untreated to be dilated
during a second elective procedure (staged revascularization). Recently, with the advent of time,
experience, expertise, and technique the multi-vessel PCI procedure became more reliable, predict-
able, and reproducible. We therefore believe that it was reasonable in our study to reinvestigate the
clinical outcomes of complete revascularization strategy during the index procedure in patients with
STEMI and multi-vessel disease.
Methods: A total of 78 patients (72 males and 6 females) with ST-elevation MI presented within
12 h from the onset of symptom who had at least two angiographically-documented diseased cor-
onary arteries (luminal diameter narrowingP70%) and received primary PCI were included. They
were randomly assigned to receive either PCI for culprit vessel only in the initial procedure (SR
group) followed by another session of angioplasty to other diseased vessels (within 7 days), or
(CR group) consisted of 42 patients who had received complete revascularization during the initial
procedure after intracoronary administration of nitroglycerin to avoid stenting of functionally non-
signiﬁcant lesions. The combined incidence of MACE including death, recurrent myocardial infarc-yahoo.com (W. Maamoun).
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40 W. Maamoun et al.tion, re-hospitalization for angina and cerebrovascular accidents during 1 year follow up was
recorded.
Results: The baseline characteristics were well balanced between the study groups with the angio-
graphic and procedural data showed no signiﬁcant difference. The study end point combining
death, MI, readmission because of recurrent ischemia or cerebrovascular accidents at 1-year fol-
low-up occurred in 19.4% of patients with the complete staged strategy and 26.2% of patients with
the complete simultaneous strategy (P= 0.5).
Conclusion: A simultaneous multi-vessel strategy during primary PCI is safe and feasible with no
clear long term beneﬁts in MACE rates over staged multi-vessel strategy. These data suggest that
the decision to perform a simultaneous complete revascularization or to limit the procedure to cul-
prit vessel only followed by elective intervention of the non-culprit vessels in patients with AMI and
multi-vessel disease remains a decision to be made by individual operators and patients.
ª 2011 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Primary percutaneous coronary intervention (PCI) is currently
the treatment of choice in patients with acute ST segment ele-
vation myocardial infarction (STEMI).1,2 Among 40–65% of
those patients have multi-vessel coronary artery disease, a neg-
ative prognostic predictor of cardiovascular morbidity and
mortality.3 Contemporary guidelines recommend to dilate only
the infarct-related-artery (culprit only revascularization) dur-
ing the urgent procedure, leaving the other stenosed vessels un-
treated to be dilated during a second elective procedure (staged
revascularization). Simultaneous treatment of IRA and non-
IRAs is recommended only in patients with cardiogenic
shock.4,5 However, it remains uncertain whether treatment of
coronary lesions of non-IRA is required, or when the proce-
dures should be performed. Recently, with the advent of time,
experience, expertise, and technique the multi-vessel PCI pro-
cedure became more reliable, predictable, and reproducible.
Few reports described outcomes of complete revascularization
compared to culprit vessel only revascularization in patients
undergoing urgent mechanical reperfusion for STEMI.6,7 We
therefore believe it was reasonable in our study to reinvestigate
the clinical outcomes of complete revascularization strategy
during the index procedure in patients with STEMI and mul-
ti-vessel disease.
2. Methods
2.1. Study population
A total of 78 patients with ST-elevation MI presented within
12 h from the onset of symptom who had at least two angio-
graphically-documented diseased coronary arteries (luminal
diameter narrowing P70%) and received primary PCI were
included during the period from 1/2007 to 12/2008 in the Uni-
versity of science and technology hospital, Yemen. Patients
with cardiogenic shock, pulmonary edema, and left main cor-
onary artery disease were excluded. In addition to those with
previous revascularization, serum creatinine level >1.4 mg/dl
and contraindication for anti-platelet therapy were also ex-
cluded. Clinical variables that included age, sex, smoking habit
and the presence or absence of diabetes, hypertension, and
hypercholesterolemia were recorded. All participants were di-
vided into two groups. Group 1 (SR) consisted of 36 patients
presented in the 1st year of the study and had undergone pri-mary PCI for culprit vessel only in the initial procedure fol-
lowed by another session of angioplasty to other diseased
vessels (within 7 days), and group 2 (CR) consisted of 42 pa-
tients presented in the 2nd year of the study and had received
complete revascularization during the initial procedure after
intracoronary administration of nitroglycerin to avoid stenting
of functionally non-signiﬁcant lesions.
3. Procedures
3.1. Coronary angiography and intervention
Pre-medications with anti-platelet therapy including aspirin
300 mg, clopidogrel 600 mg, IIb IIIa receptor antagonist be-
fore the procedure were given to all patients. Unfractionated
heparin was given before PCI as a weight-adjusted bolus of
100 IU/kg body weight. Selective coronary arteriography and
PCI were performed through femoral approach, the culprit
vessel was identiﬁed by the standard method according to
ST-segment elevation in contiguous ECG leads. Successful
PCI was deﬁned as TIMI grade 3 ﬂow of the IRA with residual
stenosis <20% without serious complications. Complete
revascularization was diagnosed if all lesions with stenosis
P70% were treated successfully after PCI. All lesions in the
culprit vessel in both groups were treated with BMSs while
the other non-culprit vessels were treated with BMSs or DESs
according to the operator decision and ﬁnancial facilities.
After the procedure, we recorded the occurrence of contrast in-
duced nephropathy which was deﬁned as an absolute increase
in serum creatinine values of P0.5 mg/dl or a P25% relative
increase from baseline within 72 h following the procedure. All
the patients with drug-eluting stents (DESs) implantation re-
ceived clopidogrel 75 mg daily for 12 months. For those who
had bare-metal stents (BMSs), clopidogrel 75 mg daily was
prescribed for 6 months. Meanwhile, all patients were given
aspirin 100 mg as maintenance dose indeﬁnitely. Statins,
b.blockers and ACE inhibitors were strongly recommended
as concomitant treatment. All patients had written consent be-
fore the initial procedure.
4. Endpoints
Patients were followed up for 12 months in the outpatient
clinic for the major adverse cardiac event (MACE), including
death (cardiac or non-cardiac), recurrent MI, rehospitalization
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cerebrovascular accidents, deﬁned as any neurologic event
whether hemorrhagic or non-hemorrhagic stroke, and bleeding
requires surgical intervention and/or blood transfusion. Car-
diac death was considered if death was caused by fatal arrhyth-
mia, heart failure, newly occurred MI, or sudden cardiac
death.
5. Statistical analysis
Measurements and categorical data were expressed as
mean ± standard deviation (SD) and percentage, respectively.
Differences between the two groups were assessed by Student’s
t-test for continuous variables or the Chi-square test for cate-
gorical variables. A P value <0.05 was considered statistically
signiﬁcant.
6. Results
Baseline clinical characteristics of the study groups are listed in
Table 1, which showed no statistical signiﬁcant differences be-
tween both groups.
6.1. Angiographic and procedural characteristics
There was no signiﬁcant difference in the angiographic and
procedural characteristics between both groups. In the SR
group, 2.22 ± 0.42 vessels per patient were treated using
2.31 ± 0.47 stents per patient vs. 2.26 ± 0.45 vessels per pa-
tient were treated using 2.38 ± 0.49 stents per patient in CR
group, P> 0.05. In group I, 68.3% BMS and 31.7% DES
were deployed vs. 64.3% BMS and 35.7% DES in group II,
P> 0.05). One patient developed contrast induced nephropa-
thy in group I (SR) vs. two patients in group II (CR), 2.8%
and 4.8%, respectively (P> 0.05) (Table 2).
6.2. One year clinical outcomes
At 1 year follow up, there were no signiﬁcant differences be-
tween patients in the SR group and the CR group as regards
the cumulative rates of recurrent MI, re-hospitalization be-
cause of recurrent ischemia, TVR, cerebrovascular accidents
and death (Table 3). Throughout the follow up, one patient
died from sudden cardiac death in the SR group while two died
in the CR group one after CVA and the other after newly oc-
curred MI (P= 0.7). The incidence of recurrent ischemia and
TVR was higher in CR group vs. the SR group but with no sta-
tistical signiﬁcance (21.4% vs. 16.7%, P= 0.6 and 14.3% vs.
11.1%, P= 0.7, respectively). The cumulative rates of MACETable 1 Comparison of baseline clinical variables for study patient
Group I (SR) (36 patients)
Age (mean) 52.33 ± 7.1
Male (No. (%)) 32 (88.9%)
BMI (mean) 20.8 ± 3.1
Smoking (No. (%)) 20 (55.6%)
Hypertension (No. (%)) 12 (33.3%)
Diabetes mellitus (No. (%)) 20 (55.6%)
Dyslipidemia (No. (%)) 16 (44.4%)
EF (mean) 45.0 ± 6.9
Anterior location (No. (%)) 25 (70%)were 19.4% for the SR group and 26.2% for the CR group
(P= 0.5).
7. Discussion
Primary angioplasty is the therapy of choice for patients with
ST-segment elevation myocardial infarction (STEMI).5 Con-
tinuous advancements in adjuvant antithrombotic strategies
coupled with reﬁnements in interventional techniques have
led to signiﬁcant improvement in procedural success and
long-term clinical outcomes.5 However, STEMI patients with
multi-vessel disease remain a major challenge. In this setting,
different studies have shown that multi-vessel disease is a ma-
jor independent predictor of adverse prognosis.8 Current clin-
ical practice guidelines recommend that in STEMI patients,
only the culprit vessel should be initially treated unless hemo-
dynamic compromise is present.5 It is an open question
whether this remains a good idea in the era of drug-eluting
stents, which have been demonstrated by randomized con-
trolled trials and observational studies to be associated with
lower subsequent revascularization rates and by several obser-
vational studies to be associated with lower mortality for pri-
mary PCI and PCI for STEMI patients.9–12
The proponents of culprit only strategy emphasize that
multi-vessel intervention is not initially required because it
may lead to prolonged interventions, contrast overload, heart
failure, and renal impairment. In addition, non-culprit lesion
severity may be exaggerated as the result of circulating cate-
cholamine-mediated vasoconstriction, and multi-vessel stent-
ing might be associated with higher rates of periprocedural
myocardial infarction, and increased rates of late revascular-
izations secondary to restenosis.7,8,13–15 Alternatively, propo-
nents of initial multi-vessel interventions argue that STEMI
patients have a heightened inﬂammatory milieu and multiple
plaque disruptions. Plaque instability is not limited to the cul-
prit lesion, and lack of therapy of the other lesions is associ-
ated with adverse events. Additionally, severe disease in non-
culprit vessels may hamper the compensatory contractility of
remote myocardial regions characteristic of STEMI patients
and impair collateral development.7,13–15 Finally, simultaneous
multi-vessel intervention limits the vascular access and antico-
agulant-related bleeding complications arising from further
procedures, as well as reducing costs.16
In fact, recent data suggest that with currently available
technologies, multi-vessel stenting can be readily and safely
performed during primary angioplasty procedures.7,14,15 Some
provocative studies challenge current recommendations and
suggest that this strategy is indeed superior to the classic ap-
proach of staged elective procedures.14 However, most of theses.
Group II (CR) (42 patients) P value
54.52 ± 10.3 0.08
40 (95.2%) 0.3
21.6 ± 2.9 0.5
22 (52.4%) 0.8
16 (38.1%) 0.7
17 (40.5%) 0.2
24 (57.1%) 0.3
45.5 ± 8.8 0.07
26 (62%) 0.5
Table 2 Comparison of procedure characteristics among study patients.
Group I (SR) (36 patients) Group II (CR) (42 patients) P value
No. of BMS stents (%) 56/82 (68.3%) 63/98 (64.3%) 0.7
No. of DES stents (%) 26/82 (31.7%) 35/98 (35.7%) 0.5
No. of stent/patient (mean) 2.31 ± 0.47 2.38 ± 0.49 0.5
No. of vessel/patient (mean) 2.22 ± 0.42 2.26 ± 0.45 0.7
No. of two vessels (%) 28 (77.8%) 31 (73.8%) 1
No. of three vessels (%) 8 (22.2%) 11 (26.2%) 1
No. of contrast induced nephropathy (%) 1 (2.8%) 2 (4.8%) 1
Table 3 Study end points and safety outcome.
Group I (SR) (36 patients) Group II (CR) (42 patients) P value
TVR (No. (%)) 4 (11.1%) 6 (14.3%) 0.7
Cerebrovascular accidents (No. (%)) 0 (0%) 3 (7.1%) 0.1
MI (No. (%)) 1 (2.8%) 1 (2.4%) 0.9
Death (No. (%)) 1 (2.8%) 2 (4.8%) 0.7
Rehospitalization (No. (%)) 6 (16.7%) 9 (21.4%) 0.6
Combined MACE (No. (%)) 7(19.4%) 11(26.2%) 0.5
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drug-eluting stent utilization.
Our study was designed to examine the clinical outcomes
among patients with STEMI and multi-vessel disease who
underwent complete simultaneous multi-vessel intervention
during the initial procedure. Those patients were compared
with a group of patients with multi-vessel disease who under-
went staged PCI within 7 days after AMI. We found no differ-
ence in the rate of individual MACE or in the cumulative rate
of MACE between the two studied groups. Previous studies of
the role of multi-vessel PCI in patients with STEMI had come
to disparate conclusions. In line with our study results; Roe
et al. retrospectively analyzed 6-months clinical outcomes for
129 patients with multi-vessel disease, of whom 61 received pri-
mary PCI for IRA only and the remaining 68 underwent
simultaneous intervention for both IRA and non-IRA lesions.
They reported an increased risk of stroke in patients who had
undergone IRA and non-IRA PCI (10.3 % vs. 0%). The rate
of composite end point of death, re-infarction, re-PCI, or cor-
onary artery bypass grafting (CABG) was similar between the
patients with multi-vessel PCI and those who had undergone
PCI for IRA only.17
Likewise, a report of Politi et al.; in which 214 patients with
STEMI and multiple coronary lesions were treated with pri-
mary PCI. Multi-vessel revascularization had better outcome
than treatment of IRA only. Both the simultaneous treatments
of non-IRA vessels and the staged approach resulted in a lower
risk of MACE compared to the culprit only procedure (63%
and 60%, respectively). Particularly, patients in culprit only
revascularization group had a higher risk of repeated un-
planned revascularization, re-hospitalization, and in-hospital
death.14 Similar rates of major adverse cardiac events at 1 year
follow up were observed also in the study groups (24% and
28% in multi-vessel and culprit treatment groups, P= 0.73)
of a single-centered prospective study for patients who had
an acute STEMI and multi-vessel disease. More interestingly,
in this study were the non-statistical signiﬁcant differences in
the ﬂuoroscopy time and contrast dye amount in both
groups.18 Finally, a recent small randomized study comparingrevascularization of multi-vessel coronary artery disease with
revascularization of the infarct related artery alone in patients
with STEMI found the incidence of major adverse cardiac
events at 1 year to be similar in the two groups15
Conversely, Corpus et al. have shown that multi-vessel PCI
was associated with high rates of re-infarction (13.0% vs.
2.8%), repeat revascularization (25% vs. 15%), and MACE
(40% vs. 28%) during a 1-year follow-up. Multi-vessel PCI
was an independent predictor forMACE inpatientswith ST-ele-
vation MI. These results further support the concept that PCI
should be reserved for IRA only in ST-elevation MI patients
with multi-vessel disease.13,17 More recently, Hannan et al.
examine the large database of the mandatory New York State’s
Percutaneous Coronary Interventions Reporting System Regis-
try (NY-PCIRS) to gain further insight into appropriate revas-
cularization strategies in STEMI patients with multi-vessel
disease. A total of 4,024 STEMI patients with multi-vessel dis-
ease undergoing primary angioplasty within 24 hwere analyzed.
Multi-vessel intervention during the index procedure was per-
formed in 503 (12.5%) patients. Of the remaining 3,521 patients,
staged interventions during admission were performed in 259
patients (7.4%), whereas staged procedures within 2 months of
STEMI were indicated in 538 (15.3%) patients. Interestingly,
drug-eluting stents alone were used in nearly two-third of cases.
For patients without hemodynamic compromise, culprit-vessel-
only intervention during the index procedure was associated
with signiﬁcantly lower in-hospital mortality than multi-vessel
intervention. Furthermore, patients undergoing staged multi-
vessel interventionwithin 2 months after STEMI, but not during
the index procedure, had a signiﬁcantly lower mortality rate
than patients undergoing culprit lesion intervention alone. This
series represents the largest systematic studywith long-term clin-
ical follow-up ever performed to address this issue. Results indi-
cate that, whenever possible, multi-vessel intervention should be
initially avoided during primary angioplasty, and also that in
STEMI patients with multi-vessel disease, a strategy aimed to
achieve complete revascularization, when addressed in staged
elective procedures, is associated with long-term clinical
beneﬁt.19
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PCI is safe and feasible with a high success rate and law com-
plication events during 1 year follow up for patients with STE-
MI treated with primary PCI.20 Additionally, Telayna et al.
reported on 403 patients with AMI undergoing either culprit
only or complete simultaneous revascularization. Complete
revascularization was associated with a trend toward improved
freedom from MACE at 1 year (93% vs. 73%, P= 0.7).21
Conclusion from these different studies is that the complete
revascularization strategy is better than the culprit only strat-
egy but the dilemma of whether complete strategy could be ob-
tained during the index procedure or not especially in the era
of DESs and the aggressive anti-platelet, anti-thrombotic ther-
apy during the setting of AMI is still unsettled .From the re-
sults of the present study, we found that simultaneous multi-
vessel intervention during the index procedure is as safe as
staged multi-vessel intervention during index hospitalization.
There are some limitations in this study. It is a single-center
facility’s experience with 1ry PCI for AMI. The sample size is
relatively small and the use of drug eluting stents for non-cul-
prit vessels only may limit the long term safety and efﬁcacy of
simultaneous complete revascularization although this factor
expected to affect both strategies. Recently, some reports indi-
cated that DES implantation of culprit vessel obviously de-
creased TVR without increasing the incidence of in-stent
restenosis, MI and death12
8. Conclusion
The ﬁndings of this study indicate that simultaneous multi-ves-
sel strategy during primary PCI is safe and feasible with no
clear long term beneﬁts in MACE rates over staged multi-ves-
sel strategy. These data suggest that the decision to perform a
simultaneous complete revascularization or to limit the proce-
dure to culprit vessel only followed by elective intervention of
the non-culprit vessels in patients with AMI and multi-vessel
disease remains a decision to be made by individual operators
and patients. We think further large randomized prospective
studies using the drug eluting stents for treatment of the culprit
vessel are needed in order to provide strong enough evidence
that may update the current recommendations for patients
with AMI and multi-vessel disease.References
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